Education
About Us
Working with TipRanks
Follow Us
EnBio Holdings, Inc. (JP:6092)
:6092
6092 Stock Chart & Stats
¥598.00
-¥2.00(-0.33%)
At close: 4:00 PM EST
¥598.00
-¥2.00(-0.33%)
Day’s Range― - ―
52-Week Range¥500.00 - ¥746.00
Previous CloseN/A
Volume5.80K
Average Volume (3M)25.91K
Market Cap
¥4.99B
Enterprise Value¥11.69B
Total Cash (Recent Filing)¥3.19B
Total Debt (Recent Filing)¥10.28B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)-75.25
Shares Outstanding8,175,200
10 Day Avg. Volume21,320
30 Day Avg. Volume25,910
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.53
Price to Sales (P/S)0.45
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained top-line growth of ~11.4% demonstrates durable demand or market expansion for EnBio's services. Over a 2-6 month horizon this underlying revenue momentum supports reinvestment capacity, scalability benefits and provides a foundation for improving margins and cash generation.
Healthy Operational MarginsGross and operating margins in the mid-teens/low-double digits indicate efficient core operations and discipline on cost structure. These margin levels create a buffer against input cost shocks, support incremental profitability as revenue grows, and make margin expansion feasible with modest operational improvements.
Balanced Capital StructureA debt-to-equity around 1.1 and a ~43% equity ratio reflect moderate leverage and a solid equity base. This balanced structure gives management flexibility to fund capex or strategic initiatives without being overlevered, reducing refinancing risk and supporting stability across business cycles.
Bears Say
Negative Free Cash FlowFCF turning negative due to elevated capex signals the company is investing heavily but currently not generating surplus cash. Persisting negative FCF strains liquidity, increases reliance on external funding, and limits the company’s ability to return capital or self-fund growth without altering spending or improving cash conversion.
Poor Cash ConversionAn OCF-to-net-income ratio of 0.05 implies reported earnings largely aren’t converting to cash. This structural inefficiency can reflect working capital pressure, non-cash accounting gains, or timing mismatches that weaken liquidity and make earnings less reliable as a source of funding for operations or investment.
Low Returns & Profitability PressureROE below 5% and a thin net margin indicate limited ability to generate returns on shareholder capital. Combined with a year-over-year decline in net income, this suggests pressure on profitability and capital efficiency that could impair long-term shareholder value unless margins or return on invested capital improve.
EnBio Holdings, Inc. News
6092 FAQ
What was EnBio Holdings, Inc.’s price range in the past 12 months?
EnBio Holdings, Inc. lowest stock price was ¥500.00 and its highest was ¥746.00 in the past 12 months.
What is EnBio Holdings, Inc.’s market cap?
EnBio Holdings, Inc.’s market cap is ¥4.99B.
When is EnBio Holdings, Inc.’s upcoming earnings report date?
EnBio Holdings, Inc.’s upcoming earnings report date is May 20, 2026 which is in 91 days.
How were EnBio Holdings, Inc.’s earnings last quarter?
EnBio Holdings, Inc. released its earnings results on Feb 13, 2026. The company reported -¥75.25 earnings per share for the quarter, missing the consensus estimate of N/A by -¥75.25.
Is EnBio Holdings, Inc. overvalued?
According to Wall Street analysts EnBio Holdings, Inc.’s price is currently Overvalued.
Does EnBio Holdings, Inc. pay dividends?
EnBio Holdings, Inc. pays a Annually dividend of ¥9 which represents an annual dividend yield of 1.54%. See more information on EnBio Holdings, Inc. dividends here
What is EnBio Holdings, Inc.’s EPS estimate?
EnBio Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EnBio Holdings, Inc. have?
EnBio Holdings, Inc. has 8,175,200 shares outstanding.
What happened to EnBio Holdings, Inc.’s price movement after its last earnings report?
EnBio Holdings, Inc. reported an EPS of -¥75.25 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.165%.
Which hedge fund is a major shareholder of EnBio Holdings, Inc.?
Currently, no hedge funds are holding shares in JP:6092
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
EnBio Holdings, Inc.
EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.
Technical Analysis
Hikari Business Form Co., Ltd.
―
CRESTEC Inc.
―
Sougou Shouken Co., Ltd.
―
Sun Messe Co., Ltd.
―
Mitsumura Printing Co., Ltd.
―